Standard

Design of 4-Substituted Sulfonamidobenzoic Acid Derivatives Targeting Coxsackievirus B3. / Шетнев, А.А.; Волобуева, А. С.; Панова, Валерия; Зарубаев, Владимир Викторович; Байков, Сергей Валентинович.

в: Life, Том 12, № 11, 1832, 09.11.2022.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Шетнев, АА, Волобуева, АС, Панова, В, Зарубаев, ВВ & Байков, СВ 2022, 'Design of 4-Substituted Sulfonamidobenzoic Acid Derivatives Targeting Coxsackievirus B3', Life, Том. 12, № 11, 1832. https://doi.org/10.3390/life12111832

APA

Шетнев, А. А., Волобуева, А. С., Панова, В., Зарубаев, В. В., & Байков, С. В. (2022). Design of 4-Substituted Sulfonamidobenzoic Acid Derivatives Targeting Coxsackievirus B3. Life, 12(11), [1832]. https://doi.org/10.3390/life12111832

Vancouver

Шетнев АА, Волобуева АС, Панова В, Зарубаев ВВ, Байков СВ. Design of 4-Substituted Sulfonamidobenzoic Acid Derivatives Targeting Coxsackievirus B3. Life. 2022 Нояб. 9;12(11). 1832. https://doi.org/10.3390/life12111832

Author

Шетнев, А.А. ; Волобуева, А. С. ; Панова, Валерия ; Зарубаев, Владимир Викторович ; Байков, Сергей Валентинович. / Design of 4-Substituted Sulfonamidobenzoic Acid Derivatives Targeting Coxsackievirus B3. в: Life. 2022 ; Том 12, № 11.

BibTeX

@article{9c1c0a7670284438b0ed26bddfc2c98c,
title = "Design of 4-Substituted Sulfonamidobenzoic Acid Derivatives Targeting Coxsackievirus B3",
abstract = "A series of novel 4-substituted sulfonamidobenzoic acid derivatives was synthesized as the structural evolution of 4-(4-(1,3-dioxoisoindolin-2-yl)phenylsulfonamido)benzoic acid, which is the known inhibitor of the enterovirus life cycle. Antiviral properties of prepared compounds were evaluated in vitro using phenotypic screening and viral yield reduction assay. Their capsid binding properties were verified in thermostability assay. We identified two new hit-compounds (4 and 7a) with high activity against the coxsackievirus B3 (Nancy, CVB3) strain with potencies (IC50 values of 4.29 and 4.22 μM, respectively) which are slightly superior to the reference compound 2a (IC50 5.54 μM). Both hits changed the heat inactivation of CVB3 in vitro to higher temperatures, suggesting that they are capsid binders, as 2a is. The results obtained can serve as a basis for further development of the lead compounds for novel drug design to combat enterovirus infection.",
keywords = "aminobenzoic acid, capsid binders, enteroviruses, heterocycles, imide, screening",
author = "А.А. Шетнев and Волобуева, {А. С.} and Валерия Панова and Зарубаев, {Владимир Викторович} and Байков, {Сергей Валентинович}",
note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",
year = "2022",
month = nov,
day = "9",
doi = "10.3390/life12111832",
language = "English",
volume = "12",
journal = "Life",
issn = "0024-3019",
publisher = "MDPI AG",
number = "11",

}

RIS

TY - JOUR

T1 - Design of 4-Substituted Sulfonamidobenzoic Acid Derivatives Targeting Coxsackievirus B3

AU - Шетнев, А.А.

AU - Волобуева, А. С.

AU - Панова, Валерия

AU - Зарубаев, Владимир Викторович

AU - Байков, Сергей Валентинович

N1 - Publisher Copyright: © 2022 by the authors.

PY - 2022/11/9

Y1 - 2022/11/9

N2 - A series of novel 4-substituted sulfonamidobenzoic acid derivatives was synthesized as the structural evolution of 4-(4-(1,3-dioxoisoindolin-2-yl)phenylsulfonamido)benzoic acid, which is the known inhibitor of the enterovirus life cycle. Antiviral properties of prepared compounds were evaluated in vitro using phenotypic screening and viral yield reduction assay. Their capsid binding properties were verified in thermostability assay. We identified two new hit-compounds (4 and 7a) with high activity against the coxsackievirus B3 (Nancy, CVB3) strain with potencies (IC50 values of 4.29 and 4.22 μM, respectively) which are slightly superior to the reference compound 2a (IC50 5.54 μM). Both hits changed the heat inactivation of CVB3 in vitro to higher temperatures, suggesting that they are capsid binders, as 2a is. The results obtained can serve as a basis for further development of the lead compounds for novel drug design to combat enterovirus infection.

AB - A series of novel 4-substituted sulfonamidobenzoic acid derivatives was synthesized as the structural evolution of 4-(4-(1,3-dioxoisoindolin-2-yl)phenylsulfonamido)benzoic acid, which is the known inhibitor of the enterovirus life cycle. Antiviral properties of prepared compounds were evaluated in vitro using phenotypic screening and viral yield reduction assay. Their capsid binding properties were verified in thermostability assay. We identified two new hit-compounds (4 and 7a) with high activity against the coxsackievirus B3 (Nancy, CVB3) strain with potencies (IC50 values of 4.29 and 4.22 μM, respectively) which are slightly superior to the reference compound 2a (IC50 5.54 μM). Both hits changed the heat inactivation of CVB3 in vitro to higher temperatures, suggesting that they are capsid binders, as 2a is. The results obtained can serve as a basis for further development of the lead compounds for novel drug design to combat enterovirus infection.

KW - aminobenzoic acid

KW - capsid binders

KW - enteroviruses

KW - heterocycles

KW - imide

KW - screening

UR - https://www.mdpi.com/2075-1729/12/11/1832

UR - https://www.mendeley.com/catalogue/ec03762e-11e0-3692-b8f3-632445c18ba6/

UR - http://www.scopus.com/inward/record.url?scp=85141726728&partnerID=8YFLogxK

U2 - 10.3390/life12111832

DO - 10.3390/life12111832

M3 - Article

VL - 12

JO - Life

JF - Life

SN - 0024-3019

IS - 11

M1 - 1832

ER -

ID: 100039083